Senseonics Holdings, Inc. (SENS) Stock Analysis and Metrics

Senseonics Holdings

NASDAQ: SENS

$4.86 ▼ -0.01 (-0.10%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap203.54 Mn

P/E-2.03

P/S5.00

Div. Yield0.00

Total Debt (Qtr)35.91 Mn

Revenue Growth (1y) (Qtr)87.17

Add ratio to table…

About

Senseonics Holdings, Inc. is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system designed to improve diabetes management. The company's primary product, the Eversense CGM system, includes the Eversense E3 and Eversense 365 systems, which measure glucose levels via an implantable sensor, a removable smart transmitter, and a mobile app for real-time monitoring. The Eversense 365 system provides up to twelve months of continuous glucose sensing, while the Eversense E3 system offers six months of use, both requiring minimal user calibration and delivering data through vibratory alerts and Bluetooth connectivity to mobile devices.

Senseonics generates revenue from the sale of its Eversense CGM system, which includes the sensor pack containing the sensor, insertion tool, and adhesive patches; the smart transmitter pack containing the transmitter and charger; and procedure revenue associated with sensor insertion and removal. Revenue is derived through direct sales to distributors and strategic fulfillment partners who supply healthcare providers and patients, as well as through a consignment model with healthcare professionals. The company relies on third-party payor coverage and reimbursement from commercial insurers and government agencies such as Medicare to drive adoption, with approximately 300 million covered lives in the United States as of 2025 through positive coverage decisions including UnitedHealthcare.

The company operates through the following segments:

• Eversense CGM Systems: This segment encompasses the development, manufacturing, and commercialization of implantable continuous glucose monitoring systems for people with diabetes. The segment includes the Eversense E3 CGM system and the Eversense 365 CGM system as its primary products. These systems are designed to provide long-term glucose monitoring with sensor durations of up to six and twelve months, respectively.

Senseonics operates in a competitive CGM market alongside well-capitalized companies such as Dexcom, Medtronic, and Abbott, which also offer FDA-approved and CE Marked CGM systems. The company differentiates itself through the extended duration of its implantable sensor, which lasts up to one year—significantly longer than the seven to 15 days typical of non-implantable CGM systems. Additional competitive advantages include on-body vibratory alerts for glucose thresholds, 24/7 patient and provider support, and the ability to share data remotely with caregivers and healthcare teams.

Senseonics serves people with diabetes, including both type 1 and type 2 patients, who require ongoing glucose monitoring to manage their condition. The company's customers include individuals using insulin pumps or multiple daily injections, as well as those managing diabetes through diet, exercise, and oral medications. Healthcare providers such as endocrinologists, primary care physicians, and certified diabetes educators are also key customers who prescribe the Eversense system and perform sensor insertions and removals.

Investment Thesis

▲ Bull case

Senseonics' successful integration of the U.S. commercial organization with Ascensia is delivering early validation of its strategy to improve financial performance through scale, as evidenced by Q1 2026 revenue of $11.7 million and a 58% gross margin, driven by higher manufacturing volumes, elimination of the Ascensia revenue share, and a strategic shift toward the more profitable bundled pay reimbursement channel; this structural improvement in margins and revenue quality positions the company to exceed its raised full-year 2026 guidance of $60–64 million, representing 70–82% year-over-year growth, as the benefits of direct commercial control compound with increasing patient retention and Eon Care's expanding role in insertion procedures, which now handles over one-third of all U.S. insertions and reduces dependency on individual physician practices, thereby lowering barriers to adoption and supporting scalable growth in a market where geographic access has historically constrained implantable CGM uptake.
The company's advancing product pipeline, including the Gemini sensor targeting first-half 2027 launch and the Freedom system preparing for first-in-human trials in the second half of 2026, represents a derisked next-generation platform that leverages proven, low-risk technologies—such as Integer's implantable batteries with over two decades of use in cardiac and neuromodulation devices and well-established Bluetooth integration pathways—minimizing technological and manufacturing uncertainty while addressing key patient pain points like transmitter dependency and frequent sensor changes; this pipeline, combined with positive real-world data from the Sequel Med Tech twiist AID integration showing strong adherence, glucometrics, and hypoglycemic outcomes, provides multiple near- and mid-term catalysts that could accelerate adoption beyond current expectations, particularly as Senseonics gains traction in the type 1 diabetes population where long-term sensor use and algorithmic precision are highly valued.
Senseonics' strengthened balance sheet, bolstered by a $92 million public offering and a $20 million draw on its expanded $140 million Hercules Capital credit facility, provides over $100 million in incremental growth capital to support commercial expansion in Europe—where Eversense 365 launches in Sweden, Spain, Germany, and Italy are progressing on schedule—and to fund continued investment in DTC marketing and Eon Care nurse recruitment, which aims to reach 100 nurses by year-end; this financial flexibility, coupled with the company's expectation that 60% of 2026 revenue will occur in the second half due to seasonal deductible resets and back-half marketing focus, creates a favorable setup for accelerated revenue recognition and margin expansion in H2 2026, especially as the European transition closes this quarter and Eon Care's geographic reach in 34 states continues to reduce friction in patient access, setting the stage for sustained top-line growth and improved operating leverage as the commercial organization achieves full integration and scale.

Senseonics' successful integration of the U.S. commercial organization with Ascensia is delivering early validation of its strategy to improve financial performance through scale, as evidenced by Q1 2026 revenue of $11.7 million and a 58% gross margin, driven by higher manufacturing volumes, elimination of the Ascensia revenue share, and a strategic shift toward the more profitable bundled pay reimbursement channel; this structural improvement in margins and revenue quality positions the company to exceed its raised full-year 2026 guidance of $60–64 million, representing 70–82% year-over-year growth, as the benefits of direct commercial control compound with increasing patient retention and Eon Care's expanding role in insertion procedures, which now handles over one-third of all U.S. insertions and reduces dependency on individual physician practices, thereby lowering barriers to adoption and supporting scalable growth in a market where geographic access has historically constrained implantable CGM uptake.
The company's advancing product pipeline, including the Gemini sensor targeting first-half 2027 launch and the Freedom system preparing for first-in-human trials in the second half of 2026, represents a derisked next-generation platform that leverages proven, low-risk technologies—such as Integer's implantable batteries with over two decades of use in cardiac and neuromodulation devices and well-established Bluetooth integration pathways—minimizing technological and manufacturing uncertainty while addressing key patient pain points like transmitter dependency and frequent sensor changes; this pipeline, combined with positive real-world data from the Sequel Med Tech twiist AID integration showing strong adherence, glucometrics, and hypoglycemic outcomes, provides multiple near- and mid-term catalysts that could accelerate adoption beyond current expectations, particularly as Senseonics gains traction in the type 1 diabetes population where long-term sensor use and algorithmic precision are highly valued.
Senseonics' strengthened balance sheet, bolstered by a $92 million public offering and a $20 million draw on its expanded $140 million Hercules Capital credit facility, provides over $100 million in incremental growth capital to support commercial expansion in Europe—where Eversense 365 launches in Sweden, Spain, Germany, and Italy are progressing on schedule—and to fund continued investment in DTC marketing and Eon Care nurse recruitment, which aims to reach 100 nurses by year-end; this financial flexibility, coupled with the company's expectation that 60% of 2026 revenue will occur in the second half due to seasonal deductible resets and back-half marketing focus, creates a favorable setup for accelerated revenue recognition and margin expansion in H2 2026, especially as the European transition closes this quarter and Eon Care's geographic reach in 34 states continues to reduce friction in patient access, setting the stage for sustained top-line growth and improved operating leverage as the commercial organization achieves full integration and scale.

▼ Bear case

Despite Senseonics' optimism about Eversense 365 adoption, the company faces significant competitive pressure from emerging long-duration and next-generation CGM systems from Dexcom, Abbott, and others that are rapidly closing the gap in sensor longevity while offering lower price points, greater convenience, and no implantable procedure—factors that could erode Eversense's core value proposition of year-long wear, particularly as patient reorder rates, while improving, remain unproven beyond the first year and may not sustain the assumed 85% first-to-second and 85% second-to-third sensor conversion trends cited by management, leaving retention assumptions vulnerable to real-world performance data that has not yet been validated at scale for multi-year use.
The company's reliance on expanding its direct-to-consumer (DTC) channel as a primary growth driver carries substantial risk, as DTC marketing efficiency remains unproven at scale despite Q1 improvements in cost per workable lead and conversion rates, and the historical pattern of elevated DTC spending in the back half of 2025 yielding only modest efficiency gains suggests that customer acquisition costs may remain structurally high, potentially undermining profitability even as revenue grows; furthermore, the shift to bundled pay reimbursement, while margin-accretive, depends on sustained physician and payer adoption that may not scale as quickly as anticipated, especially given the procedural complexity of sensor insertions and the limited availability of trained healthcare professionals outside of Eon Care's network, which, despite operating in 34 states, still leaves significant geographic gaps in access.
Senseonics' financial projections assume continued operating leverage from commercial integration, yet Q1 2026 SG&A expenses surged to $30.2 million—up $22.5 million year-over-year—driven by personnel costs, transition services, and DTC investment, with full-year 2026 operating expenses guided to $150–160 million, implying that even if revenue reaches the midpoint of $62 million, the company will remain deeply unprofitable on an EBITDA basis, and the expectation of margin expansion in the second half hinges on optimistic assumptions about reimbursement channel mix and manufacturing efficiencies that may not materialize if European launch execution falters or if supply chain constraints persist with manufacturing partners, leaving the path to profitability uncertain and highly dependent on flawless execution across multiple simultaneous initiatives.

Despite Senseonics' optimism about Eversense 365 adoption, the company faces significant competitive pressure from emerging long-duration and next-generation CGM systems from Dexcom, Abbott, and others that are rapidly closing the gap in sensor longevity while offering lower price points, greater convenience, and no implantable procedure—factors that could erode Eversense's core value proposition of year-long wear, particularly as patient reorder rates, while improving, remain unproven beyond the first year and may not sustain the assumed 85% first-to-second and 85% second-to-third sensor conversion trends cited by management, leaving retention assumptions vulnerable to real-world performance data that has not yet been validated at scale for multi-year use.
The company's reliance on expanding its direct-to-consumer (DTC) channel as a primary growth driver carries substantial risk, as DTC marketing efficiency remains unproven at scale despite Q1 improvements in cost per workable lead and conversion rates, and the historical pattern of elevated DTC spending in the back half of 2025 yielding only modest efficiency gains suggests that customer acquisition costs may remain structurally high, potentially undermining profitability even as revenue grows; furthermore, the shift to bundled pay reimbursement, while margin-accretive, depends on sustained physician and payer adoption that may not scale as quickly as anticipated, especially given the procedural complexity of sensor insertions and the limited availability of trained healthcare professionals outside of Eon Care's network, which, despite operating in 34 states, still leaves significant geographic gaps in access.
Senseonics' financial projections assume continued operating leverage from commercial integration, yet Q1 2026 SG&A expenses surged to $30.2 million—up $22.5 million year-over-year—driven by personnel costs, transition services, and DTC investment, with full-year 2026 operating expenses guided to $150–160 million, implying that even if revenue reaches the midpoint of $62 million, the company will remain deeply unprofitable on an EBITDA basis, and the expectation of margin expansion in the second half hinges on optimistic assumptions about reimbursement channel mix and manufacturing efficiencies that may not materialize if European launch execution falters or if supply chain constraints persist with manufacturing partners, leaving the path to profitability uncertain and highly dependent on flawless execution across multiple simultaneous initiatives.

Related and Nonrelated Parties Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Related and Nonrelated Parties Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Related and Nonrelated Parties Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password